Skip to main content

Table 1. Baselines characteristics of all patients

From: Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China

Characteristics Bedaquiline group (n = 102) Non-bedaquiline group (n = 100) p value
Age (years, median/IQR) 37.0 (28.0–52.0) 43.5 (29.0–54.0) 0.08
Gender (n, %), male/female 78 (76.5)/24 (23.5) 71 (71.0)/29 (29.0) 0.77
Cavitary disease at baseline (n, %) 71 (73.2) 73 (73.0) 0.65
Concomitant extra-pulmonary TB (n, %) 20 (19.6) 15 (15.0) 0.39
Concomitant diabetes (n, %) 16 (15.7) 13 (13.0) 0.59
History of TB treatment (n, %)    0.85
 New cases 9 (8.8) 8 (8.1)  
 Previously treated cases 93 (91.2) 91 (91.9)  
Type of drug resistance (n, %)    0.67
 RR 3 (2.9) 5 (5.0)  
 MDR 74 (72.5) 68 (68.0)  
 XDR 25 (24.5) 27 (27.0)  
Drug resistant rate (n, %)/n, % in XDR    
 Injectable agents 83 (81.4)/25 (100.0) 77 (77.0)/27 (100.0) 0.44/–
 FQs 61 (59.8)/25 (100.0) 55 (55.0)/27 (100.0) 0.49/–
 EMB 57 (55.9)/16 (64.0) 65 (65.0)/24 (88.9) 0.19/0.03*
 INH 97 (95.1)/23 (92.0) 98 (98.0)/26 (96.3) 0.20/0.95
  1. IQR interquartile range, M male, F female, n number, TB tuberculosis, RR rifampicin-resistant, MDR multidrug-resistant, XDR extensively drug-resistant, FQs fluoroquinolones, EMB ethambutol, INH isoniazid. Injectable agents: including Amikacin (Ak), Capremycin (Cm) and Streptomycin (Sm)
  2. * the differences had statistical significance (p < 0.05)